Beauty Brands Target Skin Sagging After Weight Loss
Companies are expanding skincare and device research to address the physical effects of rapid weight loss from obesity treatments.
Updated on Oct. 28, 2026 in Weight Loss
Live Poll
Do you believe beauty companies should specifically market new products to address effects of weight-loss drugs?
Global beauty brands are ramping up development of skincare products and home devices to manage facial skin sagging. This surge in market interest follows a significant increase in the use of GLP-1 weight loss medications, which can lead to facial fat loss.
Why it matters
Rapid weight loss from obesity treatments often results in facial skin changes that drive demand for aesthetic solutions. As GLP-1 usage grows, manufacturers are repurposing existing technologies to address this specific physical side effect.
The clinical aesthetics market for managing post-weight-loss skin changes is projected to grow to 2 billion dollars by 2031, up from a current value of 700 million dollars. Medicube's EGF NAD Elastic Ampoule has already surpassed 1 million units in cumulative sales.
The players
L'Oréal
A global personal care company that manages diverse beauty brands including SkinCeuticals and Kiehl's.
Galderma
A pharmaceutical company specializing in dermatological treatments such as Sculptra and Restylane.
Amorepacific
A South Korean beauty and cosmetics company that recently released the Sumalift home beauty device.
The details
Companies including L'Oréal, Galderma, and Natura are utilizing peptide materials and adiponectin activators to improve skin firmness. They are adapting collagen promoters and hyaluronic acid fillers specifically for those experiencing skin laxity following weight loss.
Timeline
January 2025: GLP-1 drug usage stood at 9% of U.S. households.
May 2026: U.S. household usage of GLP-1 drugs rose to 21%.
September 2026: Amorepacific launched the Sumalift beauty device.
Late September 2026: Medicube's ampoule sales reached 1 million units.
Health Landscape
The growth in the beauty market for skin elasticity directly follows the trend in rising GLP-1 medication usage identified by PwC. This shift represents a broader evolution in medical aesthetics as companies adapt to the cosmetic consequences of pharmaceutical weight loss trends.
Consumers seeking solutions for sagging skin after weight loss now have an increasing array of topical products and home devices to consider. Individuals should monitor clinical efficacy, as these products are designed specifically to address volume loss associated with pharmaceutical weight reduction.
The takeaway
Rapid weight loss can lead to visible skin changes that beauty brands are increasingly seeking to address with targeted products. Individuals navigating weight loss should consult with skincare professionals to identify which clinical aesthetic options are most appropriate for their specific skin needs.
Further reading
Learn more about the latest innovations in Weight Loss.
Source note: This article includes information reported by 조선일보.
Live Poll
Do you believe beauty companies should specifically market new products to address effects of weight-loss drugs?
